INTRODUCTION
Increased angiogenesis is a hallmark of cancer. 1 Intratumoral blood vessels not only provide nutrients and oxygen to support tumor growth, but also offer a way for cancer cells to enter the blood circulation and metastasize to distant organs. Previously it was assumed that intratumoral blood vessels mainly arise from normal blood vessel sprouting. However, it had been recognized that tumor vasculature is different from normal vessels. The tumor vessel is structurally and functionally abnormal, resulting in vascular permeability and perfusion that is temporally and spatially heterogeneous. [2] [3] [4] Cancer cells had been reported to be involved in tumor vasculature formation. The formation of fluid conducting networks by non-endothelial cells has been described for melanomas, sarcomas, breast, ovary, lung and prostate carcinomas, [5] [6] [7] as a result of vasculogenic mimicry. Recently it is reported that glioblastoma stem like cells are able to differentiate into functional endothelial cells. A subpopulation of endothelial cells within glioblastomas harbor the same somatic mutations identified within tumor cells and a subpopulation of intermediate CD133 þ CD144 þ progenitor cell was multipotent and capable of differentiation along tumor and endothelial lineages. 8, 9 These findings describe a new mechanism for tumor angiogenesis and provide new insights into the biology of cancer stem cells (CSCs).
MicroRNAs (miRNA) are functionally versatile, and have a significant role in the regulation of differentiation and stemness of embryonic stem cells. 10 Many research have shown that miRNAs also regulate self-renewal and differentiation of CSCs. [11] [12] [13] Our previous study reported that let-7, which was markedly decreased in breast cancer stem like cells (BCSLCs), helped to maintain multipotency of CSCs by regulating HMGA2. 14 However, whether miRNAs regulate the endothelial differentiation of BCSLCs is not known yet. In the present study, we examined the ability of BCSLCs to differentiate into endothelial cells, and the role of miRNAs in regulating endothelial differentiation from BCSLCs both in vitro and in vivo.
RESULTS

Vascular endothelial growth factor (VEGF)-induced endothelial differentiation of BCSLCs
To study whether BCSLCs can differentiate into endothelial cells, we cultured adherent or freshly dissociated cells from MDA-MB-231 and SK-3rd mammospheres in endothelial basal medium with or without 10 ng/ml VEGF for 2 weeks and examined them for the expression of endothelial markers including VEGFR2, CD31 and von Willebrand factor (vWF). We found that adherent MDA-MB-231 and SK-3rd cells, already differentiated from mammospheric cells, did not express any of the endothelial markers with or without VEGF treatment. Mammosphere-cultured MDA-MB-231 and SK-3rd cells expressed a small amount of VEGFR2, but no CD31 or vWF without VEGF treatment. However, after VEGF treatment, the expression of VEGFR2, CD31 and vWF were markedly induced in mammosphere-cultured cells, similar to the ones in human umbilical vein endothelial cells, shown by western blot and immunofluoresecence (Figures 1a and c) .
To determine whether these findings are clinically relevant, we isolated CD44 þ CD24 À BCSLCs from primary breast cancer samples and cultured them in endothelial basal medium with or without VEGF. Similarly, VEGF treatment significantly induced the expression of VEGFR2, CD31 and vWF in primary CD44 þ CD24 À BCSLCs, while non-CD44 þ CD24 À cells from primary breast tumor had no expression of endothelial markers with or without treatment of VEGF (Figure 1b) .
Formation of capillary-like structures in matrigel and histaminemediated release of vWF are two commonly used functional tests for endothelial cells. We then examined endothelial differentiated BCSLCs for these two functional properties. When grown in matrigel, VEGF-treated BCSLCs developed tubular and capillary-like structures, while untreated mammospheric cells or adherent cells failed to form such structure (Figure 1d ). In addition, vWF was present in the cytoplasm of BCSLCs-derived endothelial cells and significantly decreased upon histamine treatment (Figure 1e ). Collectively, these results suggest that BCSLCs are able to differentiate into cells with endothelial markers, morphology and function. miR-27a expression was elevated in endothelial differentiated BCSLCs To study whether miRNAs has a role in endothelial differentiation of BCSLCs, we used miRNA array to identify the differentially expressed miRNAs when BCSLCs induced endothelial differentiation. There were 24 miRNAs upregulated with a cutoff value of 2.5-fold in VEGF-treated BCSLCs compared with untreated BCSLCs (Figure 2a , Table 1 ). Among them, miR-27a is the most consistently and significantly increased miRNA by 15-folds. To confirm microarray results, qRT-PCR was performed to verify the expression of miR-27a. In VEGF-treated mammospheric cells, miR27a level was increased by about 6.6-folds (MDA-MB-231, Po0.005) and about 7.2-folds (SK-3rd, Po0.005) compared with untreated mammospheric cells or adherent cells (Figure 2b ). In addition, miR27a expression in VEGF-treated primary BCSLCs sorted by CD44 þ
CD24
À was elevated by about 10.2-folds (Po0.005), compared with untreated primary BCSLCs or non BCSLCs (Figure 2c) .
To examine the effect of VEGF on miR-27a function, we transfected a luciferase reporter containing a miR-27a target 3 0 UTR sequence into mammospheric MDA-MB-231 and SK-3rd cells and then treated cells with VEGF. The luciferase activity was suppressed by B50% in VEGF-treated mammospheric MDA-MB-231 and SK-3rd cells (Po0.001) (Figure 2d ). miR-27a regulates the endothelial differentiation of BCSLCs under the treatment of VEGF To test whether miR-27a is important in the endothelial differentiation of BCSLCs, we transfected miR-27a mimics into untreated BCSLCs and miR-27a anti-sense oligonucleotide (ASO) into VEGF-treated BCSLCs. miR-27a mimics restored the miRNA Figure S1) . We found that miR-27a mimics in undifferentiated BCSLCs without VEGF treatment significantly increased the protein expression of VEGFR2, CD31 and vWF while miR-27a ASO decreased the expression of the endothelial marker in VEGF-treated BCSLCs (Figure 3a and Supplementary Figure  S2A ). In addition, ectopic expression of miR-27a promoted the formation of capillary structure in untreated BCSLCs, and miR-27a ASO inhibited the formation of capillary structure in VEGF-treated BCSLCs (Figure 3b and Supplementary Figure S2B) . Further, we found that miR-27a mimics increased the expression of vWF in the cytoplasm of untreated BCSLCs by immnofluorescence and histamine induced the release of vWF from these BCSLCs. Additionally, miR-27a ASO significantly reduced the vWF level in the cytoplasm of VEGF-treated BCSLCs that was further decreased by histamine (Figure 3c and Supplementary Figure S2C) . These results indicate that miR-27a, which is increased in VEGF-treated BCSLCs, regulates the endothelial differentiation of BCSLCs under the treatment of VEGF.
ZBTB10 is a target gene of miR-27a miR-27a has been reported to regulate a zinc-finger protein ZBTB10, a repressor of Sp1. 15 Thus we examined whether ZBTB10 is changed during VEGF-induced endothelial differentiation of BCSLCs. We found that the expression of ZBTB10 was not changed in adherent MD-MBA-231 and SK-3rd cells with or without VEGF treatment (Figure 3d and Supplementary Figure S2D Abbreviations: miRNA, microRNA; PBS, phosphate-buffered saline. *Indicates an miRNA expressed at lower levels relative to the miRNA in the opposite arm of a hairpin. Figure S2F) . Thus, our data indicate that miR-27a directly inhibits ZBTB10 expression by targeting the 3 0 UTRs of ZBTB10. ZBTB10 has been shown to inhibit the expression of Sp1, a transcription factor that has been implicated in the regulation of genes needed for angiogenesis, including VEGFR2. To examine the effect of ZBTB10 on Sp1 and VEGFR2 in VEGF-induced endothelial differentiation, we tranduced VEGF-induced BCSLCs with ZBTB10-expressing vector and found that the restored ZBTB10 significantly inhibited Sp1 and VEGFR2 expression in VEGF-induced BCSLCs. In addition, knockdown of ZBTB10 in untreated BCSLCs increased Sp1 and VEGFR2 expression ( Figure 3g and Supplementary Figure S2G ).
Runx1 regulates miR-27a transcription during VEGF-induced differentiation To study how VEGF induces miR-27a transcription, we used JASPAR and TFSearch to search for potential transcription factor binding sites in miR-27a promoter. We found a highly conserved putative regulatory region containing two consensus Runx1 binding sites, about 10 kb upstream of the miR-27a locus. To examine whether Runx1 binds to this region, we performed electrophoretic mobility shift assay (EMSA) using a DIG-labeled 5 0 -mer specific probe for the miR-27a promoter. The nuclear extracts of VEGF-treated mammospheric cells, when incubated with the biotinylated miR-27a probe, resulted in a 'shift' (Lane 3; Figure 4a ). Addition of anti-Runx1 antibody resulted in 'supershift' of the protein-DNA complex (Lane 5). In order to confirm the specificity of Runx1 for the probe sequence, we also incubated nuclear extracts in presence of 100-fold excess unlabeled probe (cold probe) and observed a significant decrease in the intensity of shifted bands (Lane 4). In addition, no 'shift' was observed when the nuclear extracts were incubated with mutant probes (Lane 7, 8). These results indicate that Runx1 binds to miR-27a promoter upon VEGF treatment. Further, we used chromatin immunoprecipitation (ChIP) to evaluate whether RUNX1 binds to the miR-27a promoter with the putative Runx1 binding sites (tgcggt) and found that VEGF markedly enhanced the binding of Runx1 to this region (Figure 4b ).
To examine if Runx1 is functionally important in miR-27a transcription, we transfected MDA-MB-231 and SK-3rd cells with two Runx1 small interfering RNAs. It was found that either of the two small interfering RNAs knocked down miR-27a expression by 450% (Po0.01), while the mock and GFP control had no effect on miR-27a expression (Figure 4c ). The results suggest that, upon induction of endothelial differentiation, Runx1 binds to the regulatory region of miR-27 and upregulates its expression. miR-27a activates the autocrine VEGF signaling loop by targeting ZBTB10 Autocrine VEGF signaling loop has been previously demonstrated in breast cancer cells. 16 To study whether the VEGF loop exists in endothelial differentiation of BCSLCs, we examined VEGF level in the supernatants of the cells and found VEGF-treated BCSLCs expressed significantly more endogenous VEGF (Po0.005) than untreated BCSLCs, suggesting a positive VEGF loop during endothelial differentiation (Figure 5a ). Further, miR-27a led to more endogenous VEGF secretion in untreated BCSLCs (Po0.005) and miR-27a ASO decreased VEGF secretion in VEGF-treated BCSLCs (Po0.005) (Figure 5b ). Moreover, knockdown of ZBTB10 increased VEGF secretion in untreated BCSLCs (Po0.005) while ZBTB10 decreased VEGF expression in endothelial differentiated BCSLCs (Po0.005) (Figure 5c ). These results indicate that miR-27a regulates the VEGF signaling loop by targeting ZBTB10.
miR-27a promotes tumor growth, angiogenesis and metastasis in NOD/SCID mice We next examined the effect of miR-27a expression on tumor in vivo. The miR-27a-expressing MDA-MB-231 xenografts grew faster than the untransduced or control tumors. The miR-27a-expressing xenografts reached 2 cm in diameter 30-33 days after they became palpable, while the control tumors reached 2 cm in 39 days. ZBTB10-small hairpin RNA (shRNA) also accelerated tumor growth, but to a lesser degree than miR-27a (Figure 6a ). Using anti-human CD31 antibody to stain endothelial cells, we found that the tumors formed by cells transfected with miR-27a or ZBTB-shRNA contained significantly higher microvessel density and larger blood vessels than those formed by control cells (Figures 6b and c) , indicating that miR-27a promoted blood vessel formation. Interestingly, when we stained tumor tissue with antimouse CD31 or anti-human CD31 in serial sections, we found that most vessels in the tumor center were human-CD31-positive while the peripheral vessels were mostly positive for mouse CD31, suggesting that the center vessels are from cancer cells and the peripheral vessels are from normal adjacent tissue (Supplementary Figure S3) .
We also used transmission electron microscopy to study the ultrastructure of blood vessels in xenografts. The basement membrane underlying the endothelial cells of all groups was continuous and well formed. However, the endothelial wall in xenografts with miR-27a or ZBTB10-shRNA was thinner than that of control groups. In addition, small clusters of sprouting microvessels were relatively frequent, which generally exhibited neo-angiogenetic activity. The blood vessels extended numerous protrusions into the blood space and, also into the perivascular extracellular matrix (Figure 6d) .
Next, we wanted to study the transport capacity of xenograft blood vessels. Hoechst 33342, the fluorescence dye used to stain nuclei was employed to explore its penetration through the blood vessels of each group. The dye was injected into the mice via tail vein before the mice were killed. And the dye could penetrate through the blood vessels, which were stained by CD31, into perivascular region. The dye could reach at least three layers of tumor cells that surrounded the blood vessel in control xenografts, while the dye could only stain the cells closely surrounding the blood vessels in xenografts with miR-27a or ZBTB10-shRNA (Figure 6e) , suggesting that the blood vessels in xenografts with miR-27a or ZBTB10-shRNA exhibit poorer transport capacity than the control xenografts.
Then we evaluated whether enforced miR-27a or ZBTB10-shRNA expression in MDA-MB-231 affected metastasis by examining the lungs and livers of mice when xenografts reached 2 cm in diameter. Ectopic miR-27a expression in MDA-MB-231 cells significantly increased both the numbers of mice with lung metastases to five out of eight mice (Table 2, Po0.05). Expressing ZBTB10-shRNA in MDA-MB-231 cells modestly increased lung metastasis, but was less effective than miR-27a (Table 2, Figure 6f) . Similarly, miR-27a expression or ZBTB10 silencing increased the numbers of mice with liver metastasis by 150% and 100%, respectively (Table 2) . Collectively, these data suggest that miR27a increased metastasis of BCSLCs to lung and liver and this effect is at least partially through ZBTB10.
DISCUSSION
In this study, we have examined whether BCSLCs can differentiate into endothelial cells both morphologically and functionally and studied the role of miRNA in regulating this process. Together, our data indicate that BCSLCs can differentiate into cells with endothelial morphology and function. Furthermore, miR-27a has an important role in regulating the endothelial differentiation of BCSLCs by targeting ZBTB10 that leads to the expression of Sp1/ VEGFR2 and the positive autocrine VEGF loop. More importantly, miR-27a promotes tumor growth, angiogenesis and metastasis in an animal model, which is consistent with our recent report that miR-27 is a prognostic marker for breast cancer progression and patient survival. 17 Increased angiogenesis is crucial to cancer as rapidly growing cancer cells need extra blood supply to support its growth. It was previously thought that tumor mainly expand its vasculature by sprouting of endothelial cells from nearby normal vessels or by recruiting circulating endothelial and other cells into tumor. Recently, Wang et al. 8 and Ricci-Vitiani et al. 9 proposed a new mechanism of blood vessel formation that a significant portion of tumor endothelium came from cancer cells, but not normal tissues. Their research showed that tumor-initiating cells in glioblastoma had the ability to directly contribute to the tumor vasculature by endothelial differentiation. In the CSC model, CSCs can differentiate into multiple lineages. However, most research only focuss on their differentiation into different components of epithelium. Bussolati et al. 18 used mammosphere culture to enrich breast CSCs from one lobular infiltrating breast carcinoma sample and added VEGF to induce their differentiation into endothelium. Our data further demonstrated that BCSLCs from both cell lines and primary tissue can differentiate into cells with endothelial marker, morphology and function. These findings suggest that as tumor grows, cancer cells not only attract adjacent normal cells and tissues to form blood vessels to supply necessary nutrients and oxygen, but also can form blood vessels by themselves, which seems to be a significant way to maintain their growth.
It is well documented that miRNAs has an important role in regulating CSCs' stemness and differentiation. [11] [12] [13] We previously showed that let-7 helps to maintain CSCs multipotency by regulating HMGA2.
14 In this study, we found miR-27a expression Inhibition of miR-27a function by ASO represses angiogenesis in vitro and postnatal retinal vascular development in vivo. 19 In addition, miR-27a enhance angiogenesis by promoting angiogenic signaling through targeting Sprouty2 and Sema6A proteins, which exert antiangiogenic activity. 19 Mertens-Talcott et al. 15 also reported that transfection of antisense miR-27a results in increased expression of ZBTB10 mRNA (a SP1 suppressor) and contribute to the proliferative and angiogenic phenotype of cancer cells. However, the role of miR-27 in CSCs has not been reported yet. Our data suggest that miR-27a in undifferentiated BCSLCs and non-stem cells is low, but can be rapidly induced by VEGF during endothelial differentiation. Furthermore, miR-27a is a key regulator to sustain the autocrine VEGF signaling loop by targeting ZBTB10 and increasing VEGFR2 expression. Recent studies in the mouse also illustrated that autocrine VEGF signaling in endothelial cells is essential for vascular homeostasis. 20 Runx1, a key regulator of hemangioblast development, is critical in controlling hematopoietic cytokine receptor expression in endothelium. 21 It was also reported that Runx1 has a regulatory interplay with miR-27a during megakaryopoiesis. 22 Our results showed that under the stimulation of VEGF, Runx1 binds to the regulatory region of miR-27a. Additionaly, miR-27a expression in endothelial differentiated BCSLCs was inhibited by Runx1 knockdown. These indicate that Runx1 is an important factor in the endothelial differentiation of BCSLCs, which is in line with the notion that Runx1 has a role in hematopoiesis during development. Wang et al. 23 reported that Runx1 was expressed after treatment of VEGF during in vitro hematopoietic differentiation of human embryonic stem cells, suggesting that CSCs and embryo stem cells may share similar signal pathways during endothelial differentiation.
We found that miR-27a-expressing tumors grew faster in vivo and easily metastasize to both lung and liver. Further, the endothelial wall was thinner and fluorescence dye Hoechst 33342 stained less cells surrounding the blood vessels in miR27a or ZBTB10-shRNA groups than in control groups, indicating reduced perfusion in these tumor blood vessels. It is known that fast-growing tumor cells often produce high pressure that compresses blood and lymphatic vessels. 24 As a result of high vessel leakiness and lack of functional lymphatic drainage, interstitial fluid pressure is significantly elevated in solid tumors, [24] [25] [26] which decreases the extravasation of molecules from the bloodstream to perivascular region. In addition, abnormalities in both vasculature and viscosity lead to slow blood flow in tumor vessels. [24] [25] [26] To some extent, tumor blood flow can even reverse its direction in some vessels. 24, 25 High vessel permeability, interstitial hypertension and the changes of tumor blood flow can facilitate tumor cells to enter tumor vessels and metastasize to other organs. Our data suggested that the vasculature in mice xenograft tumor comprised two origins. The vessels in the center mainly came from human cancer cells while the peripheral vessels came from mice. This suggests that at least two mechanisms contribute to the formation of tumor vasculature to synergize to support tumor growth. Further, our results showed that expression of miR27a greatly promoted the formation and metastasis of tumor. The tumors formed by miR-27a-transfected cells contained larger and much more number of blood vessels per field, and were easily metastasized to lung or liver than those formed by control cells.
In summary, we found the BCSLCs in both primary breast cancer or cell lines can by induced by VEGF to differentiate into cells with endothelial morphology and function. miR-27a has an important role in regulating the endothelial differentiation of BCSLCs. It is possible that miR-27a could be an important target for antiangiogenic cancer therapy.
MATERIALS AND METHODS
Cell culture
MDA-MB-231 breast cancer cell line was obtained from the American Type Culture Collection (ATCC). SK-3rd cell line was previously established 14 and enriched for BCSLCs. Mammosphere culture was performed as previously reported.
14 Dissociated cells from mammospheres were cultured in endothelial basal medium (EBM, Cambrex Bio Science, Walkersville, MD, USA) with 10% fetal calf serum (FCS) and with or without VEGF (10 ng/ml, R&D Systems Inc., Minneapolis, MN, USA) for 14 days.
Tumor specimen were finely minced with scissors and then digested by incubation for 4 h at 37 1C in DMEM containing collagenase III (Worthington Biochemical, Lakewood, CA, USA). After washings in medium plus 10% fetal calf serum, the cell suspension was forced through a graded series of meshes to separate the cell components from stroma and aggregates and filtered through a 30 mm pore filter (BD Biosciences, San Diego, CA, USA). Tumor cells were cultured in DMEM medium containing 20% (v/v) fetal calf serum, 100 units/ml penicillin, 100 mg/ml streptomycin.
Flow cytometry sorting of BCSLCs
Flow cytometric cell sorting was performed on single-cell suspensions using an Epics Altra flow cytometer (Beckman Coulter, Fullerton, CA, USA). The antibodies used for cell sorting were FITC-conjugated anti-CD44 (BD Biosciences) and PE-conjugated anti-CD24 (BD Biosciences).
Western blot
Protein extracts were resolved through 10-12% SDS-polyacrylamide gel electrophoresis; transferred to PVDF membranes (Pall, Port Washington, NY, USA); probed with mouse monoclonal antibody against VEGFR2 (Abcam, Cambridge, MA, USA), vWF (Abcam), sheep polyclonal antibody against CD31 (R&D Systems Inc.), rabbit polyclonal antibody against ZBTB10 (Santa Cruz, Dallas, TX, USA), Sp1 (Abcam) or GAPDH (KangChen, Shanghai, China); probed with appropriate peroxidase-conjugated secondary antibody (Proteintech, Chicago, IL, USA); and subsequently visualized by a Gel DocTM XR þ System (Bio-Rad, Hercules, CA, USA).
Immunohistochemistry and immunofluorescence
Immunohistochemistry was performed as previously described.
14 Rabbit monoclonal anti-human CD31 (ab76533, Abcam) and rabbit polyclonal anti-mouse CD31 (ab124432, Abcam) antibodies were used as primary antibodies.
For immunofluorescent staining, cells were incubated with sheep polyclonal antibody against CD31 (R&D Systems Inc.), mouse monoclonal antibody against vWF (Abcam), followed by incubation with Alexa Fluor 488 conjugated anti-mouse IgG or Alexa Fluor 555-conjugated anti-sheep IgG (Invitrogen, Carlsbad, CA, USA). For confocal microscopy, cells on cover-slips were counterstained with Hoechst 33342 or DAPI and imaged using a confocal laser-scanning microscope (Carl Zeiss Int., Oberkochen, Germany) with a core data acquisition system (Applied Precision, Issaquah, WA, USA). Table S1 ) and mutated Runx1 binding sequence (Supplementary Table S1 ) were used. Nuclear extract were preincubated with anti-Runx1 antibody (Santa Cruz). After electrophoresis on 5% polyacrylamide gel, the gel was transferred to a nylon membrane (GE healthcare, Little Chalfont, UK). The ultra violet cross-linking was carried out for 15 min. The membrane was blocked and incubated with streptavidin-horseradish peroxidase conjugate solution.
Then it was incubated in substrate equilibration buffer followed by addition of Enhanced Chemiluminiscent reagent. Blots were developed and exposed to film.
ChIP
ChIP assays were performed using the ChIP assay kit (Upstate, Charlottesville, VA, USA) as described. Chromatin from E10 7 cells was fragmented to an average size of 500 bp using a Microson XL ultrasonic cell disruptor (Misonix, Farmingdale, NY, USA). For immunoprecipitation, 4 ml of antiRunx1 antibody (Santa Cruz) was added to 1.5 ml of soluble chromatin. Rabbit preimmune serum was used as a control. For ChIP-PCR analysis, an aliquot of precipitated DNA was analysed by PCR using primers specific for the human miR-23a-27a-24-2 upstream promoter region identified by ChIP-Seq analysis. The primer sequences are shown in Supplementary  Table S1 .
In vitro matrigel tube formation assay
In vitro formation of tubular structures was studied on growth factor reduced matrigel (BD Biosciences). Cells (4 Â 10 4 cells/well) were seeded on matrigel-coated wells (24-well plate, gelify at 37 1C for 1 h) in DMEM containing 0.25% matrigel. Cells were observed periodically with a Nikon inverted microscope. Image analysis was performed with the MicroImage analysis system.
Histamine-mediated release of vWF
BCSLCs that were cultured at 10 4 cells/well in the 24-well plates were incubated with 10 M histamine (Sigma, St Louis, MO, USA) in serum-free medium for 25 min. Cells were stained with mouse monoclonal antibody against vWF (Abcam) followed by Alexa Fluor 488 conjugated anti-mouse IgG (Invitrogen), counterstained with Hoechst 33342 and imaged using a Zeiss LSM 5 Pascal model confocal microscope (Carl Zeiss Int.).
miRNA array analysis
Total RNA enriched for small RNAs was isolated using the mirVana RNA Isolation Kit (Ambion, Austin, TX, USA), and miRNAs were then excised from RNA electrophoresed through polyacrylamide gels. miRNA array was performed as previously described. 14 qRT-PCR qRT-PCR was performed using a LightCycler Real Time PCR System. SYBR green (Molecular Probes, Eugene, OR, USA) was used to detect PCR products. All reactions were done in a 10 ml reaction volume in triplicate. Primers for mature miR-27a miRNAs and U6 snRNA were from GenePharma (GenePharma, Shanghai, China). PCR amplification consisted of 30 s of an initial denaturation step at 95 1C, followed by 40 cycles of PCR at 95 1C for 20 s, 58 1C for 20 s and 72 1C for 15 s. Standard curves were generated and the relative amount of target gene mRNA was normalized to U6 snRNA. Specificity was verified by melting curve analysis.
Small interfering RNA synthesis and transfection miR-27a mimics and ASOs, small interfering RNA targeting ZBTB10 were purchased from GenePharma company. The sequences are shown in Supplementary Table S1 . MDA-MB-231 and SK-3rd cells were seeded into two six-well plates with 2.5 Â 10 5 cells/well and grown in 2 ml DMEM (Gibco, Gaithersburg, MD, USA) supplemented with 10% fetal calf serum. The cells were transfected and analysed for qRT-PCR or western blot as previously described. Generation of miRNA and shRNA-expressing lentiviruses Oligonucleotides encoding lin-4, miR-27a or shRNA targeting ZBTB10 or GFP were synthesized according to previously published sequences and cloned under the control of the U6 promoter in the lentiviral vector lentilox pLL3.7. Generation of lentivirus vectors was performed as previously described.
14 The viral supernatant was collected 48 h after transfection, and viral titers determined by transducing HeLa cells at serial dilutions and analyzing GFP expression by flow cytometry.
ELISA
An ELISA kit (R&D Systems Inc.) for human VEGF was used to quantify the levels of VEGF produced by cancer cells in vitro. Cells were cultured in serum-free conditions, and the culture supernatants were collected after 72 h. Each sample was assayed in triplicate, and the measurement was done in three independent experiments.
Tumor implantation About 10 6 of MDA-MB-231 mammospheric cells were injected subcutaneously into the mammary fat pads of 5-week-old female NOD/SCID mice. Mice were examined by palpation for tumor formation for up to 60 days. After tumors were detected, tumor size was measured every 3 days by calipers, and tumor volume was calculated as Volume (mm 3 ) ¼ L Â W 2 Â 0.4. Mice were killed by cervical dislocation and the presence of tumor was confirmed by necropsy. Tumor engrafts, as well as whole lung and liver tissues, were harvested, weighed and used for HE staining and immunohistochemistry. Tumor formation and lung or liver metastasis were determined by microscopic examination.
Electron microscope
Tissues were immediately fixed in 2.5% glutaraldehyde in 0.1 M phosphate buffer (pH 7.4) for 4 h, washed three times in phosphate buffer, postfixed for 2 h in 1% similarly buffered OsO4, dehydrated in graded alcohol and acetone, and embedded in Epoxy resin. Thick sections, in the 1 mm range, were stained with toluidine blue, and examined by light microscopy. Suitable blocks were thin-sectioned using an LKB ultratome with a diamond knife. Sections in the gray to silver range were collected on 150-mesh grids, stained with uranyl acetate and lead citrate, and examined with a Jeol-1200EX electron microscope (Hitachi S-4800 FEG SEM, Tokyo, Japan).
Blood vessel penetration assay
Forty milligram per kilogram of Hoechst 33342 (Sigma) was injected into tumor-bearing mice via lateral tail vein. The mice were killed at 1 min postinjection and the xenografts were harvested immediately for frozen section. After blocked with PBS cotaining 5% BSA for 1 h, sections were incubated with anti-CD31 (R&D Systems Inc.) at 4 1C overnight and then secondary antibody for 1 h. The slides were examined with a microscope (Carl Zeiss Int.).
Statistical analysis
Two-tailed Student's t-test was used to determine statistical significance for the results. Po0.05 was considered to be statistically significant.
